【作者】 王珊；

【导师】 王晋芬；

【作者基本信息】 山西医科大学 ， 肿瘤学， 2008， 硕士

【摘要】 目的研究MIB1与TopoⅡα在弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma DLBCL)的表达情况,探讨其与临床分期及生存时间的关系。方法收集山西省肿瘤医院病理科在1996年-2001年确诊的DLBCL病例66例,应用免疫双标记ABC-DAB/SABAP-vector red显示CD20阳性细胞表达MIB1,ABC-DAB/免疫胶体金显示CD20阳性细胞表达TopoⅡα,不进行苏木精复染。收集临床资料并完善随访。结果MIB1与TopoⅡα标记指数与临床分期有关,在低级别临床分期(Ⅰ、Ⅱ)的表达指数低于高级别的(Ⅲ、Ⅳ),有统计学差异(P<0. 05)。MIB1与TopoⅡα的表达与生存时间呈线性相关(依次r=-0.487, 0.251, P<0.05),但与年龄、性别、B症状、LDH水平、体能状态无相关性。结论MIB1与TopoⅡα可以作为DLBCL独立的预后指标。更多还原

【Abstract】 Objective To investigate the expression of MIB1 and TopoⅡα, and their relation to the clinical grades and biological behavior in diffused large-B cell lymphomas (DLBCLs).Method 66 cases of DLBCL were selected from the Pathological Deparment of Shanxi Tumor Hospital from 1996 to 2001. An ABC method was used to detecte the expression of CD3、CD20、CD79α、Pax5, and a double immunogolden technique was used to detect the expression of MIB1 and TopoⅡα. Patients related clinical data including follow-up materials were selected.Results Expression of MIB1 and TopoⅡαwere increased along with the clinical stage of the DLBCL. There was a significant difference between more ealy stage (Ⅰ、Ⅱ)and later stage (Ⅲ、Ⅳ) in DLBCL(P<0. 05). The expression of MIB1 and TopoⅡαwere also significantly related to the survival (r=-0·487, 0·251 respectively, all P<0.05), but had no association with ages, genders, B symptoms, LDH level and performance status? (P>0.05).Conclusions Expression of MIB1 and TopoⅡαmay serve as two independent prognostic predictors in DLBCL.更多还原